within Pharmacolibrary.Drugs.ATC.A;

model A07DA53
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.013333333333333334,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.06,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00045,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07DA53</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Loperamide, in combination with other agents, is an antidiarrheal medication used to manage symptoms of acute or chronic diarrhea. It acts as a peripherally acting μ-opioid receptor agonist, reducing intestinal motility and prolonging transit time. Loperamide combinations are commonly used for symptomatic relief and are still approved and in use today globally.</p><h4>Pharmacokinetics</h4><p>No specific pharmacokinetic parameters for loperamide in combination products (ATC A07DA53) found in the literature for healthy adults or population subgroups.</p><h4>References</h4><ol><li><p>Kamali, F, &amp; Huang, ML (1996). Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. <i>British journal of clinical pharmacology</i> 41(2) 125–128. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1996.tb00169.x&quot;>10.1111/j.1365-2125.1996.tb00169.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8838438/&quot;>https://pubmed.ncbi.nlm.nih.gov/8838438</a></p></li><li><p>Dean, RL, et al., &amp; Deaver, DR (2012). Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats. <i>Pharmacology, biochemistry, and behavior</i> 100(3) 530–537. DOI:<a href=&quot;https://doi.org/10.1016/j.pbb.2011.10.019&quot;>10.1016/j.pbb.2011.10.019</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22056608/&quot;>https://pubmed.ncbi.nlm.nih.gov/22056608</a></p></li><li><p>Griffith, JI, et al., &amp; Elmquist, WF (2022). Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity. <i>The Journal of pharmacology and experimental therapeutics</i> 380(1) 34–46. DOI:<a href=&quot;https://doi.org/10.1124/jpet.121.000821&quot;>10.1124/jpet.121.000821</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34663676/&quot;>https://pubmed.ncbi.nlm.nih.gov/34663676</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07DA53;
